"Visit the UCLA Health website for coronavirus updates."

During the past decade, UCLA Hematology/Oncology conducted 66 clinical trials. In the 10-year time frame, 66 clinical trials started and 39 clinical trials were completed, i.e. on average, 59.1% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 25 clinical trials were completed. i.e. 96.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Hematology/Oncology" #1 sponsor was "Pfizer" with 31 trials, followed by "Hoffmann-La Roche" with 12 trials sponsored, "Incyte Corporation" with 4 trials sponsored, "Arcus Biosciences, Inc." with 2 trials sponsored and "Astellas Pharma Global Development, Inc." with 2 trials sponsored. Other sponsors include 44 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Hematology/Oncology" #1 collaborator was "Medivation, Inc." with 6 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Hematology/Oncology" are "Melanoma" (9 trials), "Breast Neoplasms" (7 trials), "Breast Cancer" (6 trials), "Colorectal Cancer" (6 trials) and "Solid Tumors" (6 trials). Many other conditions were trialed in "UCLA Hematology/Oncology" in a lesser frequency.

Most popular intervention types in "UCLA Hematology/Oncology" are "Drug" (93 trials), "Biological" (15 trials), "Other" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (4 trials), "Pembrolizumab" (4 trials), "Talazoparib" (4 trials) and "Tocilizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Hematology/Oncology" are 92 trials for "All" genders, 5 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "UCLA Hematology/Oncology". undefined are not yet recruiting, 14 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 54 completed trials in UCLA Hematology/Oncology, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Hematology/Oncology, 43 "Phase 1" clinical trials were conducted, 40 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".